The short version of GHRH analogue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-12 and is reviewed periodically as new material appears.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
=== Medicine === MALDI-TOF spectra are often utilized in tandem with other analysis and spectroscopy techniques in the diagnosis of diseases. MALDI/TOF is a diagnostic tool with much potential because it allows for the rapid identification of proteins and changes to proteins without the cost or computing power of sequencing nor the skill or time needed to solve a crystal structure in X-ray crystallography. One example of this is necrotizing enterocolitis (NEC), which is a devastating disease that affects the bowels of premature infants. The symptoms of NEC are very similar to those of sepsis, and many infants die awaiting diagnosis and treatment. MALDI/TOF was used to identify bacteria present in the fecal matter of NEC positive infants. This study focused on characterization of the fecal microbiota associated with NEC and did not address the mechanism of disease. There is hope that a similar technique could be used as a quick, diagnostic tool that would not require sequencing. Another example of the diagnostic power of MALDI/TOF is in the area of cancer. Pancreatic cancer remains one of the most deadly and difficult to diagnose cancers. Impaired cellular signaling due to mutations in membrane proteins has been long suspected to contribute to pancreatic cancer. MALDI/TOF has been used to identify a membrane protein associated with pancreatic cancer and at one point may even serve as an early detection technique. MALDI/TOF can also potentially be used to dictate treatment as well as diagnosis.
=== De-dollarization === Business-studies academic Tim Beal views the U.S.'s imposition of financial sanctions as a factor increasing dedollarization efforts, citing responses such as the Russian-developed System for Transfers of Financial Messages (SPFS), the China-supported Cross-Border Interbank Payment System (CIPS), and the European Instrument in Support of Trade Exchanges (INSTEX) that followed the U.S.'s withdrawal from the Joint Comprehensive Plan of Action (JCPOA) with Iran. Historian Renate Bridenthal wrote that "the most looming blowback to US sanctions policy is the growing set of challenges to dollar hegemony," citing the use of local currencies to trade with sanctioned countries and attempts by Russia and China to increase the gold backing of their respective currencies.
In addition, this technology enables remote communities as First Nations people, to have access to laboratory testing, thereby allowing for more assertive health care. POCT includes: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing (such as COVID-19 rapid tests), cholesterol screening and emerging technologies in micronutrient deficiency screening and diagnosis of acute febrile illness. Lab-on-a-chip technologies are one of the main drivers of point-of-care testing, especially in the field of infectious disease diagnosis. These technologies enable different bioassays such as microbiological culture, PCR, ELISA to be used at the point of care. POCT is often accomplished through the use of transportable, portable, and handheld instruments (e.g., blood glucose meter, nerve conduction study device) and test kits (e.g., CRP, HBA1C, Homocystein, HIV salivary assay, etc.). Small bench analyzers or fixed equipment can also be used when a handheld device is not available—the goal is to collect the specimen and obtain the results in a very short period of time at or near the location of the patient so that the treatment plan can be adjusted as necessary before the patient leaves.
=== No development reported === Guanfacine extended release (Connexyn; Intuniv; Intuniv XR; S-877503; SHP-503; SPD-503) – α2-adrenergic receptor agonist [23] Riluzole sublingual (BHV-0223; Nurtec) – various actions [24] Sertraline (Aremis; Besitran; CP-51974; Gladem; Lustral; Serad; Serlain; Tatig; Zoloft) – selective serotonin reuptake inhibitor (SSRI) [25]
Sources: en.wikipedia.org
Untreated transgender people experience high rates of depression, anxiety, addiction, and suicide compared to the general population. In systematic reviews, hormone therapy and gender-affirming surgery were associated with improved mental health outcomes. In follow-up studies, most trans people experience improved psychological, social, and sexual functioning, improved global functioning, and significantly reduced suicidal ideation. Less than 1% of post-operative trans patients regret surgery. Gender-affirming surgery alone may not eliminate dysphoria or suicidality, and some trans people may need further mental health care in addition to surgery. Some researchers have expressed a need for further high-quality research on mental health outcomes following gender-affirming treatments. Certain statistically robust study designs, such as randomized controlled trials, are not applicable in studying some aspects of transgender health care due to ethical concerns (for example, it would be severely unethical to test the long-term efficacy of hormone therapy by treating some prospective patients with a placebo) as well as methodological hurdles (largely because affirmative treatments have evident effects on physiology, thus compromising blinding).
Taylor (2015) reported that the perceived self-efficacy and perceived helplessness subscales tended to estimate scores reliably across levels of the latent variables except among respondents with exceptionally low levels of perceived helplessness and exceptionally high levels of perceived self-efficacy. Finally, much less is known about the reliability of scores from the 4-item form.
=== Translational repression === The translation initiation factor eIF4E is tightly regulated by the fragile X mental retardation protein (FMRP), which controls the translation of specific mRNAs at synapses. FMRP interacts with CYFIP1, which directly binds eIF4E at a domain structurally analogous to those found in canonical 4E-binding proteins such as EIF4EBP1, EIF4EBP2, and EIF4EBP3. This interaction competitively inhibits eIF4G binding, thereby blocking assembly of the eukaryotic translation initiation complex and repressing translation. The FMRP–CYFIP1–eIF4E complex is further stabilized by dendritically localized, non-coding RNAs such as BC1, which enhance FMRP-CYFIP1 interactions and mediate recruitment to specific target mRNAs. This repressive complex is responsive to neuronal stimulation. Synaptic activity promotes the dissociation of CYFIP1 from eIF4E, thereby allowing eIF4G to bind and initiate translation. This mechanism enables dynamic, activity-dependent regulation of protein synthesis at the synapse, contributing to processes such as synaptic plasticity and learning. Since eIF4E is an initiation factor that is relatively low in abundance, eIF4E can be controlled at multiple levels. Regulation of eIF4E may be achieved at the levels of transcription, RNA stability phosphorylation, subcellular localization and partner proteins.
=== Interventions Testing Program === The Interventions Testing Program (ITP) is one of three National Institute on Aging (NIA)-supported testing sites that comprise the nationally coordinated Interventions Testing Program. The ITP was established by the NIA to rigorously evaluate pharmacological, nutritional, and biological interventions with the potential to extend lifespan, improve healthspan, and delay the onset of age-related diseases. Through a highly standardized, multi-institutional testing framework, the Program identifies interventions that target the fundamental biology of aging rather than individual diseases, providing critical preclinical evidence to guide future translational and clinical research. The Barshop Institute serves as a major testing center within the national ITP consortium, collaborating closely with partner institutions to conduct large-scale lifespan and healthspan studies using genetically heterogeneous mouse models. Unlike studies utilizing inbred strains, the genetically diverse mice employed by the ITP more closely reflect the genetic variability observed in human populations, increasing the translational relevance of study findings. Candidate interventions are proposed by investigators from across the scientific community and undergo a rigorous scientific review process before being selected for testing.
1936: Danish seismologist and geophysicist Inge Lehmann discovered that the Earth has a solid inner core distinct from its molten outer core. 1937: Canadian forensic pathologist Frances Gertrude McGill assisted the Royal Canadian Mounted Police in establishing their first forensic detection laboratory. 1937: Suzanne Comhaire-Sylvain became the first female Haitian anthropologist and the first Haitian person to complete a PhD, receiving her doctoral degree from the University of Paris. 1937: Marietta Blau and her student Hertha Wambacher, both Austrian physicists, received the Lieben Prize of the Austrian Academy of Sciences for their work on cosmic ray observations using the technique of nuclear emulsions. 1938: Nigerian physician Elizabeth Abimbola Awoliyi became the first woman to be licensed to practise medicine in Nigeria after graduating from Trinity College Dublin and the first West African female medical officer with a license of the Royal Surgeon (Dublin). 1938: Canadian geologist Alice Wilson became the first woman appointed as Fellow to the Royal Society of Canada. 1938: South African naturalist Marjorie Courtenay-Latimer discovered a living coelacanth fish caught near the Chalumna river. The species had been believed to be extinct for over 60 million years. It was named latimeria chalumnae in her honour.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.